



RealRate

PHARMACEUTICAL 2022











PHARMACEUTICAL 2022





Entrada Therapeutics Inc. Rank 19 of 466

The relative strengths and weaknesses of Entrada Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Entrada Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Entrada Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 296%, being 218% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	298,700
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,719
Liabilities, Non-Current	0
Other Assets	872
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	396
Other Net Income	-31
Other Revenues	0
Property and Equipment	6,261
Research and Development	35,926
Selling, General and Administrative Expense	15,201

Output Variable	Value in 1000 USD
Assets	305,833
Liabilities	7,115
Expenses	51,127
Revenues	0
Stockholders Equity	298,718
Net Income	-51,158
Comprehensive Net Income	-51,158
Economic Capital Ratio	296%

